NCT07822737

Brief Summary

This prospective cohort study aims to determine whether high-risk coronary plaques identified by novel Photon-Counting Detector CT (PCCT) independently predict future major adverse cardiovascular events (MACE). Participants will be followed for MACE and revascularization. The primary hypothesis is that the incidence of MACE is significantly higher in patients with PCCT-defined high-risk plaque than in those without. Additionally, patients will undergo Optical Coherence Tomography (OCT) and angiography within a month after PCCT; PCCT results will be compared with OCT in a cross-sectional analysis, and diagnostic performance will be evaluated against follow-up data.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
51mo left

Started Jan 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress29%
Jan 2025Dec 2030

Study Start

First participant enrolled

January 18, 2025

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

July 12, 2026

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 16, 2026

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2028

Expected
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2030

Last Updated

September 16, 2026

Status Verified

July 1, 2026

Enrollment Period

4 years

First QC Date

July 12, 2026

Last Update Submit

September 14, 2026

Conditions

Keywords

Photon-Counting Computed TomographyCoronary Artery DiseaseHigh risk plaque

Outcome Measures

Primary Outcomes (1)

  • Incidence of major adverse cardiovascular events (MACE)

    Incidence of major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and hospitalization for unstable angina requiring urgent revascularization, stratified by the presence versus absence of PCCT-defined high-risk plaque.

    Up to 24 months

Secondary Outcomes (2)

  • Per-lesion MACE

    Up to 24 months

  • Myocardial infarction

    Up to 24 months

Other Outcomes (1)

  • Diagnostic accuracy of PCCT for detecting OCT-defined high-risk plaque

    up to 12 month

Study Arms (2)

PCCT High-Risk Plaque Group

Participants with PCCT-defined high-risk plaque in at least one native coronary artery. High-risk plaque is defined as the presence of ≥2 of the following features on PCCT: low-attenuation plaque (\<30 Hounsfield Units), positive remodeling (remodeling index ≥1.1), spotty calcification (\<3 mm), and the napkin-ring sign.

PCCT Non-High-Risk Plaque Group

Participants without PCCT-defined high-risk plaque (0 or 1 high-risk feature) in any imaged coronary segment.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient with coronary artery disease

You may qualify if:

  • Age ≥18 years
  • Scheduled for clinically indicated, non-emergent invasive coronary angiography
  • Provision of written informed consent and willingness to comply with long-term follow-up

You may not qualify if:

  • Estimated glomerular filtration rate \<45 mL/min/1.73 m²
  • Known allergy to iodinated contrast media
  • Pregnancy or breastfeeding
  • Persistent atrial fibrillation or other arrhythmia precluding adequate ECG-gated CT acquisition
  • Body mass index \>40 kg/m²
  • Target vessel with a previously implanted stent
  • Life expectancy \<2 years or any condition that, in the opinion of the investigator, makes follow-up unlikely or participation inappropriate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Chaoyang Hospital,Capital Medical University, Beijing

Beijing, China, 10000, China

RECRUITING

MeSH Terms

Conditions

Coronary Artery DiseasePlaque, Amyloid

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Central Study Contacts

Bin Tu, MD.PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief of the Cardia department

Study Record Dates

First Submitted

July 12, 2026

First Posted

September 16, 2026

Study Start

January 18, 2025

Primary Completion (Estimated)

December 30, 2028

Study Completion (Estimated)

December 30, 2030

Last Updated

September 16, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations